癌症发展经历极其复杂的生物分子演变，且体液免疫炎症变化一直伴随着癌症发展全过程。本项目以申请人在血液中发现的个体化疾病特异性蛋白质复合物为基础，首先研制满足临床快速定量该类蛋白质复合物要求的技术平台。利用该平台快速测定肺癌、胃癌、结直肠癌和多发性骨髓瘤随访患者血液中该类复合物的量。研究上述肿瘤患者预后不同时间点的血液中该类复合物的变化规律与疾病复发或转移的关系；研究该类复合物主要成分触珠蛋白糖基化修饰与这些肿瘤预后的关系。获得这类复合物量变或触珠蛋白“质变”(分子结构变化)与这些肿瘤预后的关系，确认该类个体化、疾病特异性蛋白质复合物和疾病特异性触珠蛋白糖基化修饰在这些肿瘤预后评估中的临床应用价值,为这些肿瘤的个体化预后监测提供新型的标志物及其快速检测技术平台。

The occurrence of cancer undergoes a very complicated evolution of biomolecules, along with inflammation and immune response in the whole process. In this study, on the basis of personalized disease-specific immunoinflammation-related protein complexes (IIRPCs) discovered by our group, we first develop a rapid quantitative analytical technology and method for these IIRPCs. Using this platform is to quantify the levels of serum IIRPCs of long-term follow-up patients with lung cancer, gastric cancer, colorectal cancer and multiple myeloma. To investigate the relationship between the levels of these IIRPCs and the prognosis of these patients with different cancers and between haptoglobin glycosylation and the prognosis of these patients with different cancers. To obtain the relationship between the changes in the levels of these IIRPCs or changes in structure of haptoglobin and the prognosis of these patients. To confirm the clinical application values of cancer prognosis of these IIRPCs and haptoglobin glycosylation. Finally, this study will provide a novel personalized biomarkers for cancer prognosis monitoring and the rapid detection method for these IIRPCs.